Related Experiment Video
Updated: Jun 22, 2026

Strategies for Tracking Anastasis, A Cell Survival Phenomenon that Reverses Apoptosis
Published on: February 16, 2015
Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis
Joseph E Aslan1, Huihong You, Danielle M Williamson
1Vollum Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Abstract:
TRAIL selectively kills diseased cells in vivo, spurring interest in this death ligand as a potential therapeutic. However, many cancer cells are resistant to TRAIL, suggesting the mechanism mediating TRAIL-induced apoptosis is complex. Here we identify PACS-2 as an essential TRAIL effector, required for killing tumor cells in vitro and virally infected hepatocytes in vivo. PACS-2 is phosphorylated at Ser437 in vivo, and pharmacologic and genetic studies demonstrate Akt is an in vivo Ser437 kinase. Akt cooperates with 14-3-3 to regulate the homeostatic and apoptotic properties of PACS-2 that mediate TRAIL action. Phosphorylated Ser437 binds 14-3-3 with high affinity, which represses PACS-2 apoptotic activity and is required for PACS-2 to mediate trafficking of membrane cargo. TRAIL triggers dephosphorylation of Ser437, reprogramming PACS-2 to promote apoptosis. Together, these studies identify the phosphorylation state of PACS-2 Ser437 as a molecular switch that integrates cellular homeostasis with TRAIL-induced apoptosis.
Insights
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance in cancer cells is complex. Researchers found PACS-2, a protein, acts as a key TRAIL effector, with its phosphorylation state regulating cell death.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent for selectively eliminating diseased cells.
- However, resistance to TRAIL in many cancer cells indicates a complex underlying apoptotic mechanism.
Purpose of the Study:
- To identify key effectors mediating TRAIL-induced apoptosis.
- To elucidate the regulatory mechanisms controlling PACS-2 function in TRAIL-mediated cell death.
Main Methods:
- In vitro and in vivo studies using cancer cells and hepatocytes.
- Pharmacologic and genetic manipulation of PACS-2 and Akt pathways.
- Analysis of protein phosphorylation and interactions (PACS-2 Ser437, Akt, 14-3-3).
Main Results:
- PACS-2 was identified as an essential effector for TRAIL-induced apoptosis in tumor cells and infected hepatocytes.
- Akt phosphorylates PACS-2 at Ser437, and this phosphorylation, in conjunction with 14-3-3 binding, represses apoptosis and mediates membrane cargo trafficking.
- TRAIL treatment induces dephosphorylation of PACS-2 Ser437, thereby activating its apoptotic function.
Conclusions:
- The phosphorylation state of PACS-2 Ser437 acts as a molecular switch, integrating cellular homeostasis with TRAIL-induced apoptosis.
- Targeting the PACS-2 phosphorylation pathway could overcome TRAIL resistance in cancer therapy.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Caspases
The Extrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Apoptosis

